Publications by authors named "O B McDonald"
Objective: Acute intranasal (IN) instillation of lupus-prone NZBWF1 mice with crystalline silica (cSiO) triggers robust lung inflammation that drives autoimmunity. Prior studies in other preclinical models show that soluble epoxide hydrolase (sEH) inhibition upregulates pro-resolving lipid metabolites that are protective against pulmonary inflammation. Herein, we assessed in NZBWF1 mice how acute IN cSiO exposure with or without the selective sEH inhibitor TPPU influences lipidomic, transcriptomic, proteomic, and histopathological biomarkers of inflammation, fibrosis, and autoimmunity.
View Article and Find Full Text PDFArticle Synopsis
- Autoimmune metaplastic atrophic gastritis (AMAG) is a chronic condition affecting gastric cells, leading to iron deficiency and pernicious anemia, and is traditionally thought to primarily affect older White Northern European women.
- A study conducted at the University of Miami assessed 1,708 gastric biopsies and found a 4.6% prevalence of AMAG, significantly higher than the 1.1% seen in a previously studied Baltimore population, indicating a potential demographic difference in affected groups.
- Most AMAG patients in the Miami study were Hispanic (76%), with a median age of 60 years, suggesting a need for increased awareness and diagnostic consideration of AMAG in diverse populations.
Helicobacter pylori (H. pylori) infection is the main risk factor for gastric cancer. The SRY-Box Transcription Factor 9 (SOX9) serves as a marker of stomach stem cells.
View Article and Find Full Text PDFPurpose: TGFβ signaling is implicated in the progression of most cancers, including esophageal adenocarcinoma (EAC). Emerging evidence indicates that TGFβ signaling is a key factor in the development of resistance toward cancer therapy.
Experimental Design: In this study, we developed patient-derived organoids and patient-derived xenograft models of EAC and performed bioinformatics analysis combined with functional genetics to investigate the role of SMAD family member 3 (SMAD3) in EAC resistance to oxaliplatin.